Vitiligo, an autoimmune skin condition that causes depigmentation, can have a large effect on a patient’s quality of life and psychosocial well-being.
Nada Elbuluk, MD, and David Rosmarin, MD, discuss screening patients with vitiligo for common comorbidities.
Nada Elbuluk, MD, and David Rosmarin, MD, provide an overview of vitiligo, its prevalence, and potential triggers.
At the 2022 Fall Clinical Dermatology Conference, 5 practitioners share their best tips for treating their patients
Data demonstrates an increase in the proportion of patients achieving regimentation with longer duration of ruxolitinib cream treatment.
Improvement of vitiligo repigmentation in patients can result in higher Vitiligo Noticeability Scale values when assessed from patient-reported outcome measures (PROMs) versus traditional investigator-assessed studies.
The search for the causes of vitiligo continues. The findings in this study stand in contrast to another one conducted in eastern China that showed a high percentage of children with vitiligo had thyroid abnormalities.
A recent review article lists six other JAK inhibitors that might be used as treatments for vitiligo in addition to ruxolitinib, the active ingredient in recently approved Opzelura.
A case study reviewed an 11-year-old male for loss of pigmentation of the right side of his back and right arm.